About us Contacts Drug interactions: 390 212
Drug search by name

Selegiline transdermal and Zyvox (Linezolid Suspension)

Determining the interaction of Selegiline transdermal and Zyvox (Linezolid Suspension) and the possibility of their joint administration.

Check result:
Selegiline transdermal <> Zyvox (Linezolid Suspension)
Relevance: 19.07.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

If you are currently being treated with selegiline, let your doctor know before you receive linezolid. Combining these medications can increase the risk of a rare but serious condition called the serotonin syndrome, which may include symptoms such as confusion, hallucination, seizure, extreme changes in blood pressure, increased heart rate, fever, excessive sweating, shivering or shaking, blurred vision, muscle spasm or stiffness, tremor, incoordination, stomach cramp, nausea, vomiting, and diarrhea. Depending on your condition, your doctor may want you to discontinue selegiline for at least two weeks before you start treatment with linezolid. Otherwise, you will need to be closely monitored by your doctor during treatment. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

CONTRAINDICATED: Linezolid is a reversible, nonselective inhibitor of monoamine oxidase and may have additive pharmacologic effects with other monoamine oxidase inhibitors (MAOIs). Theoretically, coadministration may increase the risk of a hypertensive crisis. Cases of hypertension with fatal and nonfatal stroke have been reported in patients who were switched from phenelzine or isocarboxazid to tranylcypromine without a sufficient washout period. However, data are not available for linezolid, which is a weaker MAOI. Concomitant use of linezolid with other MAOIs may also increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Rare cases of serotonin syndrome have been reported in association with linezolid when used with other serotonergic agents.

MANAGEMENT: The use of linezolid concurrently or within two weeks of taking any drug that inhibits monoamine oxidase A or B is generally considered contraindicated. In emergency situations requiring urgent treatment with linezolid (e.g., vancomycin-resistant Enterococcus faecium (VRE) infections; nosocomial pneumonia and complicated skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus), the availability of alternative interventions should be considered in patients already receiving a MAOI and the benefit of linezolid treatment should be weighed against the risk of serotonin toxicity. If linezolid is required, the MAOI must be immediately stopped, and the patient closely monitored for emergent symptoms of CNS toxicity for two weeks (five weeks if fluoxetine was taken) or until 24 hours after the last dose of linezolid, whichever comes first. Patients and/or their caregivers should be advised to seek medical attention if potential symptoms of serotonin syndrome develop. Treatment with the MAOI may be resumed 24 hours after the last dose of linezolid.

References
  • FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Serious CNS reactions possible when linezolid (Ayvox) is given to patients taking certain psychiatric medications. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm265305.htm#table." ([2011 July 26]):
  • "Product Information. Xadago (safinamide)." US WorldMeds LLC, Louisville , KY.
  • Paladino JA "Linezolid: an oxazolidinone antimicrobial agent." Am J Health Syst Pharm 59 (2002): 2413-25
  • "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.
Selegiline transdermal

Generic Name: selegiline

Brand name: Eldepryl, Zelapar, Emsam

Synonyms: Selegiline

Zyvox (Linezolid Suspension)

Generic Name: linezolid

Brand name: Zyvox

Synonyms: Zyvox

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.